论文信息 - A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU). - 字舞流文

A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).

H. Hansen | J. Vibe-Petersen | E. Bork | H. Møller

[1] M. Rabinovitz,et al. Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity. , 1985, Journal of the National Cancer Institute.

[2] H. Hansen,et al. 1-2(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): a comparison of drug administration at four-week and six-week intervals. , 1973, European journal of cancer.

[3] H. Hansen,et al. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). , 1971, Cancer research.

[4] J. Edmonson,et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. , 1965, Cancer research.

[5] H. Hansen,et al. In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines , 2004, Cancer Chemotherapy and Pharmacology.